A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the six months ended June 30, 2024 and June 30, 2023 is as follows (in thousands):


Six Months Ended June 30, 2024	Contingent Consideration Liability Related to Acquisition of:
	Arkis		Location in Financial Statements	Derma Sciences		ACell		Surgical Innovations Associates (SIA), Inc.			Location in Financial Statements
Balance as of January 1, 2024	$	15,755		$	2,557	$	300		68,700
Payment									(12,400)
Change in fair value of contingent consideration liabilities	(934)		Research and development	75		—			3,200			Selling, general and administrative
Balance as of June 30, 2024	14,821			2,632		300			59,500

Short-Term	$	8,244		$	—	$	—		$	19,200		Accrued expenses and other current liabilities
Long-Term	6,577			2,632		300			40,300			Other liabilities
Total	14,821			2,632		300			59,500


Six Months Ended June 30, 2023	Contingent Consideration Liability Related to Acquisition of:
	Arkis		Location in Financial Statements	Derma Sciences		ACell		Surgical Innovations Associates (SIA), Inc.		Location in Financial Statements
Balance as of January 1, 2023	$	12,895		$	230	$	3,700	$	57,607
Change in fair value of contingent consideration liabilities	3,081		Research and development			(2,200)		5,200		Selling, general and administrative
Balance as of June 30, 2023	$	15,976		$	230	$	1,500	$	62,807

Short-Term	$	4,389		$	—	$	—	$	12,700	Accrued expenses and other current liabilities
Long-Term	11,587			230		1,500		50,107		Other liabilities
Total	15,976			230		1,500		62,807